We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know
Read MoreHide Full Article
In the latest trading session, Novavax (NVAX - Free Report) closed at $12.82, marking a +1.26% move from the previous day. The stock's performance was ahead of the S&P 500's daily loss of 0.02%. On the other hand, the Dow registered a loss of 0.35%, and the technology-centric Nasdaq decreased by 0.15%.
The stock of vaccine maker has risen by 32.01% in the past month, leading the Medical sector's gain of 1.06% and the S&P 500's gain of 2.05%.
The investment community will be paying close attention to the earnings performance of Novavax in its upcoming release. It is anticipated that the company will report an EPS of -$0.33, marking a 46.77% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $50.61 million, reflecting a 28.15% fall from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of -$0.38 per share and a revenue of $377.43 million, demonstrating changes of -114.73% and -66.4%, respectively, from the preceding year.
Investors should also note any recent changes to analyst estimates for Novavax. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 16.88% upward. Novavax is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 160, positioning it in the bottom 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know
In the latest trading session, Novavax (NVAX - Free Report) closed at $12.82, marking a +1.26% move from the previous day. The stock's performance was ahead of the S&P 500's daily loss of 0.02%. On the other hand, the Dow registered a loss of 0.35%, and the technology-centric Nasdaq decreased by 0.15%.
The stock of vaccine maker has risen by 32.01% in the past month, leading the Medical sector's gain of 1.06% and the S&P 500's gain of 2.05%.
The investment community will be paying close attention to the earnings performance of Novavax in its upcoming release. It is anticipated that the company will report an EPS of -$0.33, marking a 46.77% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $50.61 million, reflecting a 28.15% fall from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of -$0.38 per share and a revenue of $377.43 million, demonstrating changes of -114.73% and -66.4%, respectively, from the preceding year.
Investors should also note any recent changes to analyst estimates for Novavax. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 16.88% upward. Novavax is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 160, positioning it in the bottom 35% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.